Evidence network for deaths_(OS)

1IMpassion-031 (all population), 20201OlympiA (BIG 6-13, NSABP B-55), 0placeboplacebo plus SoCcarboplatin plus nab-paclitaxeldurvalumab alonepembrolizumab aloneatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideatezolizumab plus carboplatin plus nab-paclitaxelolaparibdirect evidencenetwork meta-analysis
T vs. C placeboplacebo plus SoCcarboplatin plus nab-paclitaxeldurvalumab alonepembrolizumab aloneatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideatezolizumab plus carboplatin plus nab-paclitaxelolaparib
placebo---NANANANANANANA
placebo plus SoCNA---NANANANANANA
carboplatin plus nab-paclitaxelNANA---NANANANANA
durvalumab aloneNANANA---NANANANA
pembrolizumab aloneNANANANA---NANANA
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideNANANANANA---NANA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANA---NA
olaparibNANANANANANANA---

pathologies: 142,305,306 - treatments: 483 result logic